Generate Biomedicines releases corporate presentation on programmable biology platform and clinical-stage pipeline

Generate Biomedicines, Inc.

GENB

0.00

Generate Biomedicines highlighted GB-0895, an anti-TSLP monoclonal antibody in Phase 3 for severe asthma with twice-yearly dosing.
GB-0895 features a 98-day human half-life, 106 fM binding affinity, 20x stronger than tezepelumab based on public labeling comparisons.
Late-stage COPD plans were outlined, with Phase 1b data expected in 2026.
GB-4362, a free-MMAE neutralizing antibody for use with MMAE ADCs, is slated for Phase 1 first-patient dosing in June 2026.
Pipeline also includes GB-5267, a MUC16 armored CAR-T in metastatic ovarian cancer with Phase 1 initiation targeted in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.